Farmers Trust Co. reduced its stake in Eli Lilly And Co (NYSE:LLY) by 0.6% in the 4th quarter, HoldingsChannel reports. The firm owned 28,037 shares of the company’s stock after selling 157 shares during the quarter. Farmers Trust Co.’s holdings in Eli Lilly And Co were worth $3,245,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Csenge Advisory Group acquired a new stake in Eli Lilly And Co in the 3rd quarter valued at $58,000. Cornerstone Advisors Inc. grew its stake in shares of Eli Lilly And Co by 21.3% during the third quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock valued at $83,000 after acquiring an additional 136 shares in the last quarter. Welch Group LLC acquired a new stake in shares of Eli Lilly And Co during the third quarter valued at about $123,000. Zions Bancorporation acquired a new stake in shares of Eli Lilly And Co during the third quarter valued at about $128,000. Finally, Mainstay Capital Management LLC ADV grew its stake in shares of Eli Lilly And Co by 98.0% during the third quarter. Mainstay Capital Management LLC ADV now owns 1,218 shares of the company’s stock valued at $131,000 after acquiring an additional 603 shares in the last quarter. Hedge funds and other institutional investors own 77.00% of the company’s stock.
Shares of NYSE:LLY opened at $119.16 on Friday. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $119.84. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $123.73 billion, a price-to-earnings ratio of 27.84, a PEG ratio of 1.78 and a beta of 0.33.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be paid a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.17%. The ex-dividend date of this dividend is Thursday, February 14th. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 52.57%.
In related news, SVP Myles O’neill sold 25,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $112.92, for a total transaction of $2,823,000.00. Following the sale, the senior vice president now directly owns 26,562 shares in the company, valued at approximately $2,999,381.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 51,766 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $117.74, for a total transaction of $6,094,928.84. Following the sale, the insider now owns 117,963,538 shares in the company, valued at $13,889,026,964.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,579,806 shares of company stock worth $110,738,418. 0.11% of the stock is owned by insiders.
LLY has been the subject of several recent analyst reports. JPMorgan Chase & Co. set a $117.00 target price on Eli Lilly And Co and gave the company an “overweight” rating in a research note on Wednesday, September 26th. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research note on Thursday, September 27th. Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, September 28th. SunTrust Banks lifted their price target on Eli Lilly And Co from $105.00 to $123.00 and gave the stock a “buy” rating in a research note on Monday, October 1st. Finally, ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd. Ten analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $111.50.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Quick Ratio
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.